• CFRA maintains a "Hold" rating for Novartis (NYSE:NVS) with a price target of $126, indicating stability in its stock value.
• Zacks Investment Research identifies Novartis as a top value stock, highlighting its potential for long-term investment success.
• With a market capitalization of approximately $241.14 billion and a slight increase in stock price, Novartis demonstrates solid fundamentals and a strong market position.

Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its innovative medicines and treatments. The company operates in various segments, including pharmaceuticals and oncology, and competes with other major pharmaceutical companies like Pfizer and Roche. On October 29, 2025, CFRA maintained its "Hold" rating for NVS, with the stock priced at $123.56 and a price target set at $126, as reported by StreetInsider.

Zacks Investment Research highlights Novartis as a top value stock for long-term investment. The company is recognized for its potential to outperform the market, making it an attractive option for investors. Zacks Premium provides tools like the Zacks Rank and Zacks Industry Rank to help investors make informed decisions, emphasizing Novartis's strong market position.

Currently, NVS is trading at $123.59 on the NYSE, showing a slight increase of 0.16, or 0.13%. The stock has fluctuated between $121.65 and $123.91 today. Over the past year, it has reached a high of $133.55 and a low of $96.06, indicating some volatility but also potential for growth.

Novartis's market capitalization is approximately $241.14 billion, reflecting its significant presence in the healthcare industry. With a trading volume of 1,377,675 shares, the stock remains actively traded, suggesting continued investor interest. The company's strong fundamentals and market position make it a compelling choice for long-term investors.